1. IMagyn050 YO39523/GOG-3015/ENGOT-ov39 Recruitment Update
17 Jun 2018

2. ENGOT Ov-39 Trial IMaGYN 050 Study Design
Study Design in Neoadjuvant Cohort
Previously untreated ovarian, fallopian tube, or peritoneal cancer
Stage III / IV, Unresectable advanced stage patients for neoadjuvant therapy
ECOG PS 0-2
R 1:1
Carboplatin AUC 6
Bev 15 mg/kg X 16 cycles
Placebo q3w X 22 cycles
Paclitaxel 175 mg/m2
Bev 15 mg/kg
Atezo 1200 mg q3w X 22 cycles
No cross-over
SURGERY
Key Points:
Reason for NACT must be disease-related (e.g., location/bulk of disease making patient unresectable to R0), based on Fagotti
Interval surgery must be b/w C3 & D4
No bev C3 & C4 b/c of surgery

3. IMagyn050 Recruitment Summary (as of 17 Jun 2018)
Number Of
Last Month (31 May 2018)
Current Month (17 Jun
2018)
Target for Month %
Countries Open 22
100 %
Sites Activated
278+39*
279+39*
284
98%
Sites Screening
215+12*
217+14* -
78%
Pts In-Screening 52
Enrollment
Adjuvant
362
395
Neoadjuvant
328
330
Neoadjuvant Biomarker 24
Cumulative Total
690
725
601
120%
Recr Rate
(Pts/site/mo)
0.45
0.13
Screen Failures**
156 (19%)
172 (19%)
* US satellite sites
** Overall SF% = SF Pts / (Rand Pts + SF Pts)

4. IMagyn050 Recruitment Summary (as of 17 Jun 2018)

5. IMagyn050 Countries Summary (as of 17 Jun 2018)
Countries (Community)
Site Activation
Planned Actual
Recruitment
Planned Actual
USA (GOG)
132
550
290
Austria (AGO Austria) 4 10 8
Belgium (BGOG) 38 7
Czech Rep(CEEGOG) 17 12
Denmark (NSGO) 2 13 1
Finland (NSGO) 3 9
Norway (NSGO) 11
Sweden (NSGO) 16
France (GINECO) 39
Germany (AGO) 20 65 22
Greece (HECOG) 5 37
Israel (ISGO)
Italy (MaNGO) 29
Italy (MITO) 42 34
Poland (PGOG) 6 15
Spain (GEICO) 35
Turkey (TRSGO) 26
Japan (Chugai)
120 67
China
150
Australia 18
Brazil 14
Russian Federation
South Korea 31
Region / Community
Total Recruitment
Planned Actual % of Goal
GOG (US)
550
290
52.7%
ENGOT (EU)
420
204
48.6%
Chugai(Japan)
120 67
55.8%
China
150 34
22.7%
ROW 60
130
216.7%